Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways

The identification and characterization of the components of individual signal transduction cascades, and advances in our understanding on how these biological signals are integrated in cancer initiation and progression, have provided new strategies for therapeutic intervention in solid tumors and h...

Descripción completa

Detalles Bibliográficos
Autor principal: García-Echeverría, Carlos
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721773/
https://www.ncbi.nlm.nih.gov/pubmed/18523868
http://dx.doi.org/10.1007/s11302-008-9111-5
_version_ 1782170235617411072
author García-Echeverría, Carlos
author_facet García-Echeverría, Carlos
author_sort García-Echeverría, Carlos
collection PubMed
description The identification and characterization of the components of individual signal transduction cascades, and advances in our understanding on how these biological signals are integrated in cancer initiation and progression, have provided new strategies for therapeutic intervention in solid tumors and hematological malignancies. To this end, pharmaceutical efforts have been directed to target different components of the Ras/Raf/MEK and PI3K/PKB pathways. This review article covers recent salient achievements in the identification and development of Raf, MEK, and PI3K inhibitors.
format Text
id pubmed-2721773
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-27217732009-08-05 Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways García-Echeverría, Carlos Purinergic Signal Review The identification and characterization of the components of individual signal transduction cascades, and advances in our understanding on how these biological signals are integrated in cancer initiation and progression, have provided new strategies for therapeutic intervention in solid tumors and hematological malignancies. To this end, pharmaceutical efforts have been directed to target different components of the Ras/Raf/MEK and PI3K/PKB pathways. This review article covers recent salient achievements in the identification and development of Raf, MEK, and PI3K inhibitors. Springer Netherlands 2008-06-04 2009-03 /pmc/articles/PMC2721773/ /pubmed/18523868 http://dx.doi.org/10.1007/s11302-008-9111-5 Text en © Springer Science+Business Media B.V. 2008
spellingShingle Review
García-Echeverría, Carlos
Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
title Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
title_full Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
title_fullStr Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
title_full_unstemmed Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
title_short Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
title_sort protein and lipid kinase inhibitors as targeted anticancer agents of the ras/raf/mek and pi3k/pkb pathways
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721773/
https://www.ncbi.nlm.nih.gov/pubmed/18523868
http://dx.doi.org/10.1007/s11302-008-9111-5
work_keys_str_mv AT garciaecheverriacarlos proteinandlipidkinaseinhibitorsastargetedanticanceragentsoftherasrafmekandpi3kpkbpathways

Ejemplares similares